# Hypertension Clinical Trials

Use hypertension trial evidence to select treatment thresholds and targets, verify uncontrolled blood pressure outside the office, intensify multidrug therapy appropriately, and reserve renal denervation for carefully selected patients after adherence, measurement, and secondary causes have been addressed.

**Clinical question:** How should U.S. clinicians apply hypertension trial evidence to treatment targets, medication intensification, and renal denervation selection?

Updated: 2026-08-24T16:24:02.672909+00:00

## What matters in practice
- For most treated adults with hypertension, target blood pressure is <130/80 mm Hg if tolerated; for noninstitutionalized, ambulatory, community-dwelling adults aged 65 years or older, target systolic blood pressure is <130 mm Hg. [1][3]
- Confirm an initial office-based hypertension diagnosis with out-of-office measurement; ambulatory blood pressure monitoring is the reference standard. [6]
- Use initial combination therapy when blood pressure is >20/10 mm Hg above target; preferred foundational classes are an ACE inhibitor or ARB, a thiazide-type diuretic, and/or a calcium-channel blocker. [3]
- Apparent resistant hypertension requires ambulatory confirmation, adherence assessment, and exclusion of secondary hypertension before labeling treatment resistance or considering a device procedure. [8]
- Renal denervation produces modest average blood-pressure reductions versus control in randomized evidence and should not replace optimized pharmacotherapy or diagnostic evaluation. [12][8]

## Apply intensive blood pressure targets when benefit exceeds treatment burden

Use average blood pressure and patient tolerance rather than a single office measurement to guide treatment intensity.

The ACC/AHA treatment target for most adults with hypertension is <130/80 mm Hg when tolerated. For noninstitutionalized, ambulatory, community-dwelling adults aged 65 years or older, use systolic blood pressure <130 mm Hg as the target if tolerated. The change from prior <140/90 mm Hg goals was driven by SPRINT and subsequent trial syntheses showing lower cardiovascular event rates with more intensive control. [1][3]

Do not treat a numerical target in isolation. In older adults, dizziness with intensive control and possible ischemic risk at very low diastolic pressure can alter the benefit-harm balance; one cohort analysis associated diastolic blood pressure <60 mm Hg with higher cardiovascular event risk among high-risk treated patients whose systolic blood pressure was <130 mm Hg. Reassess symptoms, orthostatic measurements, coronary disease burden, and adherence burden before further intensification. [5]

Trial evidence supports initiation of pharmacologic therapy at an average systolic blood pressure ≥140 mm Hg for primary or secondary prevention. In patients with diabetes, chronic kidney disease, or coronary artery disease, lower targets may be beneficial, but subgroup evidence is less precise; individualize intensification when adverse effects, frailty, or low diastolic pressure limit treatment. [4][5]
- Use <130/80 mm Hg as the general treated target if tolerated. [1][3]
- For ambulatory, community-dwelling adults aged ≥65 years, pursue systolic blood pressure <130 mm Hg if tolerated. [1][3]
- Pause escalation or deintensify when symptomatic dizziness, clinically important orthostasis, or concern for low-diastolic ischemia changes the risk-benefit balance. [5]

*Trial-informed target selection and clinical modifiers. [1][3][5]*

| Clinical setting | Blood pressure objective | Decision modifier |
| --- | --- | --- |
| Most adults receiving antihypertensive therapy | <130/80 mm Hg if tolerated. [1][3] | Assess adverse effects and treatment burden during titration. [5] |
| Noninstitutionalized, ambulatory, community-dwelling adults aged ≥65 years | Systolic blood pressure <130 mm Hg if tolerated. [1][3] | Use clinical judgment for substantial comorbidity or limited life expectancy. [3] |
| High cardiovascular-risk patient with treated systolic blood pressure <130 mm Hg | Avoid reflexive intensification for diastolic lowering alone. [5] | Diastolic blood pressure <60 mm Hg has been associated with higher cardiovascular event risk in a cohort analysis. [5] |
| Average systolic blood pressure ≥140 mm Hg | Initiate antihypertensive medication for primary or secondary prevention. [4] | Use repeated average measurements rather than an isolated reading. [4] |

## Confirm the blood pressure phenotype before escalating long-term therapy

Out-of-office blood pressure separates sustained hypertension from office-measurement discordance and guides resistant hypertension evaluation.

After an elevated office blood pressure suggests hypertension, confirm the diagnosis with ambulatory blood pressure monitoring or home blood pressure monitoring. The U.S. Preventive Services Task Force identifies ambulatory monitoring as the reference standard for out-of-office confirmation, and higher out-of-office blood pressure confers cardiovascular risk independent of office blood pressure. [6]

When interpreting ambulatory monitoring using thresholds historically corresponding to office blood pressure ≥140/90 mm Hg, elevated daytime blood pressure is ≥135/85 mm Hg, 24-hour blood pressure is ≥130/80 mm Hg, and nighttime blood pressure is ≥120/70 mm Hg. Use the 24-hour result to establish whether apparent office treatment failure represents sustained uncontrolled blood pressure rather than an office-only elevation. [6]

For treated patients with persistently elevated office readings, obtain home or ambulatory data before adding medications when feasible. This step is particularly important before classifying resistant hypertension or referring for renal denervation, because resistant hypertension requires elevated ambulatory blood pressure despite optimized treatment after adherence and secondary causes have been addressed. [8]
- Use ambulatory blood pressure monitoring to confirm an initial hypertension diagnosis when available. [6]
- Interpret sustained ambulatory elevation with daytime ≥135/85 mm Hg, 24-hour ≥130/80 mm Hg, or nighttime ≥120/70 mm Hg using thresholds aligned with office ≥140/90 mm Hg. [6]
- Do not call hypertension resistant on office readings alone; require elevated ambulatory blood pressure after confirming adherence and excluding secondary hypertension. [8]

*Out-of-office blood pressure thresholds historically corresponding to office blood pressure ≥140/90 mm Hg. [6]*

| Measurement period | Elevated threshold | Clinical use |
| --- | --- | --- |
| Daytime ambulatory blood pressure | ≥135/85 mm Hg. [6] | Supports sustained hypertension when office readings are elevated. [6] |
| 24-hour ambulatory blood pressure | ≥130/80 mm Hg. [6] | Use to confirm uncontrolled ambulatory blood pressure in apparent resistant hypertension. [8] |
| Nighttime ambulatory blood pressure | ≥120/70 mm Hg. [6] | Identifies nocturnal ambulatory blood pressure elevation. [6] |
| Home blood pressure monitoring | Validated out-of-office approach; no specific threshold reported here. [6] | Useful for longitudinal self-monitoring and treatment titration. [6][7] |

## Use trial-supported combination therapy rather than sequential low-intensity monotherapy

Choose complementary first-line classes and intensify early when baseline blood pressure is substantially above goal.

For most adults requiring drug treatment, select from an ACE inhibitor or ARB, a thiazide-type diuretic, and a calcium-channel blocker; combination therapy is advised in most adults with hypertension. The ACC/AHA approach favors chlorthalidone among thiazide-type diuretics because it was used in many landmark event-based randomized trials. [3]

Initiate two agents when systolic blood pressure is ≥140 mm Hg or diastolic blood pressure is ≥90 mm Hg and the average pressure is >20/10 mm Hg above the individual target. This strategy is intended to shorten time above target and avoid serial monotherapy escalation in markedly uncontrolled hypertension. [3]

For Black patients beginning drug therapy, include a thiazide-type diuretic or calcium-channel blocker in the initial regimen. Fixed-dose combinations can simplify treatment, but many U.S. combination products contain hydrochlorothiazide rather than chlorthalidone and may use lower diuretic doses than trial-based chlorthalidone regimens; assess the actual ingredients before assuming class equivalence. [3]
- Build initial regimens from an ACE inhibitor or ARB, a thiazide-type diuretic, and/or a calcium-channel blocker. [3]
- Start combination therapy when average blood pressure is >20/10 mm Hg above target. [3]
- Use a thiazide-type diuretic or calcium-channel blocker in initial therapy for Black patients. [3]
- Prefer chlorthalidone when choosing a thiazide-type diuretic on the basis of its landmark event-trial use. [3]

*Medication-intensification decisions supported by hypertension guideline and trial evidence. [3]*

| Presentation | Regimen decision | Practical caveat |
| --- | --- | --- |
| Blood pressure near target but persistently elevated | Titrate or add a complementary first-line class. [3] | Confirm out-of-office blood pressure when office and home values diverge. [6] |
| Average blood pressure >20/10 mm Hg above target | Initiate two-drug combination therapy. [3] | Use complementary classes: ACE inhibitor or ARB, thiazide-type diuretic, and/or calcium-channel blocker. [3] |
| Black patient starting treatment | Include a thiazide-type diuretic or calcium-channel blocker. [3] | Combination therapy is specifically recommended in this population. [3] |
| Selecting a thiazide-type diuretic | Consider chlorthalidone. [3] | Its preference reflects use in landmark event-based trials. [3] |

## Establish true resistance before considering renal denervation

The procedure pathway begins with ambulatory confirmation, adherence verification, and evaluation for secondary hypertension.

Treat apparent resistant hypertension as a diagnostic category first. True resistant hypertension is elevated ambulatory blood pressure despite optimized antihypertensive therapy in a patient who is fully adherent after secondary hypertension has been excluded. Therefore, reconcile every drug and dose, assess adherence directly, obtain ambulatory blood pressure monitoring, and complete secondary-cause evaluation before escalating to a device-based intervention. [8]

Renal denervation should not be positioned as a substitute for optimized multidrug therapy. Earlier randomized evidence did not support routine use of renal denervation, baroreflex activation therapy, or arteriovenous anastomosis in most patients with resistant hypertension. More recent randomized trial synthesis found a mean office systolic blood pressure difference of −8.5 mm Hg, 24-hour systolic blood pressure difference of −3.6 mm Hg, and daytime ambulatory systolic blood pressure difference of −3.9 mm Hg favoring renal denervation at primary follow-up. [8][12]

Use the ambulatory effect size when counseling patients: the pooled between-group 24-hour systolic reduction was modest, and the meta-analysis found no significant difference in serious adverse events at primary follow-up across four trials reporting this outcome. A patient considering renal denervation should understand that drug therapy, adherence, and blood pressure monitoring remain necessary after the procedure. [12]
- Require elevated ambulatory blood pressure, optimized therapy, adherence, and exclusion of secondary hypertension before diagnosing true resistant hypertension. [8]
- Do not use renal denervation routinely for most resistant hypertension presentations. [8]
- Counsel that renal denervation lowered 24-hour systolic blood pressure by a pooled mean of 3.6 mm Hg versus control at primary follow-up. [12]
- Continue medication optimization and out-of-office monitoring after any renal denervation procedure. [8][12]

### Renal denervation selection discussion

Consider renal denervation only after documenting persistent uncontrolled ambulatory blood pressure despite optimized therapy and after resolving pseudo-resistance from nonadherence, office-only elevation, or a secondary hypertensive disorder. The expected benefit is a modest average ambulatory systolic reduction rather than assured normalization, so procedural consideration is most defensible when the patient accepts that continued pharmacotherapy and surveillance are required. [8][12]
- Expected pooled effect versus control: office systolic blood pressure −8.5 mm Hg, 24-hour systolic blood pressure −3.6 mm Hg, and daytime systolic blood pressure −3.9 mm Hg at primary follow-up. [12]
- Serious adverse events were not significantly different in four trials reporting them at primary follow-up. [12]

*Stepwise distinction between apparent and true resistant hypertension and the renal denervation decision. [8][12]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Elevated office blood pressure on multiple medications | Apparent resistance; office readings alone do not establish true resistant hypertension. [8] | Obtain ambulatory blood pressure monitoring. [6][8] |
| Normal ambulatory blood pressure | Office-measurement discordance rather than sustained uncontrolled ambulatory hypertension. [6][8] | Avoid procedure referral based on office readings alone; use home or ambulatory monitoring for follow-up. [6] |
| Elevated ambulatory blood pressure with uncertain medication exposure | Pseudo-resistance from nonadherence remains possible. [8][9] | Reconcile regimen and assess adherence before changing to device therapy. [8][9] |
| Elevated ambulatory blood pressure after optimized treatment, adherence confirmation, and exclusion of secondary hypertension | True resistant hypertension. [8] | Continue optimized pharmacotherapy; discuss renal denervation only with realistic expectations of modest ambulatory blood-pressure lowering. [8][12] |

## Match the trial question to the clinical decision

Avoid extrapolating a blood pressure target trial, measurement study, or device trial beyond its tested clinical purpose.

Target trials support lower achieved blood pressure goals but do not eliminate the need for individualized tolerability assessment. SPRINT and subsequent syntheses supported more intensive control, whereas evidence in diabetes, chronic kidney disease, and coronary artery disease supports lower targets with less precise subgroup estimates; use comorbidity to increase attention to cardiovascular risk, not to bypass adverse-effect assessment. [1][2][5]

Measurement trials and observational evidence establish that office and out-of-office pressures are not interchangeable. When the question is whether to diagnose hypertension, escalate a regimen, or classify treatment resistance, ambulatory monitoring answers a different and more actionable question than a repeat office reading. [6][8]

Device trials answer whether renal denervation adds blood-pressure lowering over control, not whether it replaces medicines. The pooled ambulatory systolic effect is smaller than the office effect, reinforcing the need to use 24-hour blood pressure rather than office response alone to judge procedural benefit. [12]
- Use intensive-target evidence to guide goals, then individualize for tolerability and low-diastolic risk. [1][3][5]
- Use ambulatory monitoring to adjudicate diagnosis and apparent treatment resistance. [6][8]
- Judge renal denervation by ambulatory as well as office blood pressure; pooled 24-hour systolic benefit was 3.6 mm Hg versus control. [12]

*Clinical questions and the hypertension evidence type that should drive the decision. [1][6][8][12]*

| Clinical question | Most useful evidence framework | Actionable output |
| --- | --- | --- |
| What blood pressure should this treated patient reach? | Intensive versus standard target trials and guideline synthesis. [1][2][3] | Generally target <130/80 mm Hg if tolerated. [1][3] |
| Is hypertension sustained outside the office? | Ambulatory or home blood pressure measurement evidence. [6] | Confirm with ambulatory monitoring when possible. [6] |
| Is this patient truly resistant to treatment? | Ambulatory confirmation plus adherence and secondary-cause assessment. [8] | Require elevated ambulatory blood pressure after optimized treatment and exclusion of pseudo-resistance. [8] |
| Should renal denervation be considered? | Randomized device trials and meta-analysis. [12] | Discuss modest average ambulatory systolic lowering only after establishing true resistance. [8][12] |

## References
1. Guideline-Driven Management of Hypertension — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318083
2. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/hyp.0000000000000065
3. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2022.07.005
4. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYP.0000000000000249
5. Hypertension Pharmacological Treatment in Adults — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.18192
6. Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review | Hypertension Research — www.nature.com — https://www.nature.com/articles/s41440-022-01137-2
7. Hypertension Management and Cardiovascular Risk ... — www.nature.com — https://www.nature.com/nature-index/topics/l4/hypertension-management-and-cardiovascular-risk-reduction
8. Diagnosis and management of resistant hypertension: state of the art | Nature Reviews Nephrology — www.nature.com — https://www.nature.com/articles/s41581-018-0006-6
9. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial | Hypertension Research — www.nature.com — https://www.nature.com/articles/s41440-021-00754-7
10. Renal denervation in the antihypertensive arsenal – knowns... : Journal of Hypertension — journals.lww.com — https://journals.lww.com/jhypertension/_layouts/15/oaks.journals/downloadpdf.aspx?an=00004872-202210000-00002
11. Renal denervation for treatment of drug-resistant hypertension - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S105017381400187X
12. Renal denervation for uncontrolled hypertension: a... : Journal of Hypertension — journals.lww.com — https://journals.lww.com/jhypertension/fulltext/2024/07000/renal_denervation_for_uncontrolled_hypertension__a.2.aspx
13. Renal denervation: Alternative treatment options for hypertension? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0033062019301677
14. Renal denervation in the antihypertensive arsenal... : Journal of Hypertension — journals.lww.com — https://journals.lww.com/jhypertension/fulltext/2022/10000/renal_denervation_in_the_antihypertensive_arsenal.2.aspx
15. Renal Denervation Effects on Blood Pressure in Resistant ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/clc.70104
16. Clinical benefits and safety of renal denervation in severe ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jch.14005
17. Renal Denervation for Treating Resistant Hypertension ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2013/513214
18. Taming resistant hypertension: The promise of novel ... — bpspubs.onlinelibrary.wiley.com — https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16247
19. Renal Denervation Revisited: Promising Treatment for ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/j.1751-7176.2011.00563.x?scrollTo=references
20. Hypertension in chronic kidney disease—treatment standard ... — academic.oup.com — https://academic.oup.com/ndt/article/38/12/2694/7207411
21. Aldosterone-targeted therapies: early implementation in ... — academic.oup.com — https://academic.oup.com/eurheartj/article/46/27/2618/8111531
22. 2025 Update on resistant hypertension in CKD: where do we stand and where do we go? | Clinical Kidney Journal | Oxford Academic — academic.oup.com — https://academic.oup.com/ckj/article/18/Supplement_2/ii10/8266526
23. Hypertension in Chronic Kidney Disease (CKD): Diagnosis ... — academic.oup.com — https://academic.oup.com/ajh/article/34/4/318/6040792
24. Guideline for the pharmacological treatment of hypertension in ... — iris.who.int — https://iris.who.int/server/api/core/bitstreams/622f9611-5ad0-473e-8178-5314862a0360/content

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.